Exosens
Exosens engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. It offers image intensifier tubes; ultraviolet, short, medium, and long wave infrared, visible - near infrared, and mid-wave infrared cameras, as well as enhanced vi… Read more
Exosens (H8Y) - Total Liabilities
Latest total liabilities as of June 2025: €437.82 Million EUR
Based on the latest financial reports, Exosens (H8Y) has total liabilities worth €437.82 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Exosens - Total Liabilities Trend (2021–2024)
This chart illustrates how Exosens's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Exosens Competitors by Total Liabilities
The table below lists competitors of Exosens ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ChinaSoft International Ltd
PINK:CFTLF
|
USA | $6.81 Billion |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
China | CN¥2.80 Billion |
|
Simplo Technology Co Ltd
TWO:6121
|
Taiwan | NT$34.66 Billion |
|
Sumco Corporation
PINK:SUMCF
|
USA | $480.60 Billion |
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
India | ₹18.74 Billion |
|
Koza Altin Islemeleri A S
PINK:KOZAY
|
USA | $110.21 Million |
|
Elekta AB (publ)
PINK:EKTAF
|
USA | $2.07 Billion |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
China | CN¥2.14 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Exosens's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exosens's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exosens (2021–2024)
The table below shows the annual total liabilities of Exosens from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €404.40 Million | -10.60% |
| 2023-12-31 | €452.35 Million | +30.66% |
| 2022-12-31 | €346.20 Million | +20.04% |
| 2021-12-31 | €288.41 Million | -- |